Best Target therapy for lung cancer doctors: TOP 21 doctors

Dr. Mustafa Solak is a medical oncologist with expertise in breast, testicular, ovarian, lung, head-neck, and gastrointestinal cancers. He graduated from Hacettepe University School of Medicine. He completed his residency at Istanbul Sisli Etfal Teaching and Research Hospital. He then pursued a fellowship at Hacettepe University Cancer Institute.

Dr. Solak has managed many complex cancer cases. He has contributed to clinical advancements at respected centers, including the University of Texas MD Anderson Cancer Center. He has also worked at Hitit University Corum Training Hospital and Medical Park Hospital. His experience shows a strong commitment to cancer care and research.

Dr. Serdar Turhal is a highly experienced oncologist specializing in medical oncology and chemotherapy for breast cancer at Anadolu Medical Center. He is a member of many international oncology associations and has authored numerous articles in international publications. He specializes in prognostic factors and the therapy of malignant gastrointestinal neoplasms. To receive a consultation from Dr. Turhal, please submit a request on Bookimed.

Dr. Ofer Merimsly is the best sarcoma, lymphoma, and lung cancer doctor within Israel and in the world. Also specializes in Whipple surgery treatment for patients with pancreatic cancer. Head of the National Center for sarcomas of bone and soft tissues of the Tel Aviv Medical Center Sourasky (Ichilov).

Specialty:

• Treatment of all types of lung cancer and thoracic organs
• Treatment of all types of sarcomas of bone and soft tissue
• Treatment stromal tumors of the gastrointestinal tract

Education and specialization:

• Higher medical education, graduated the Medical Faculty of the Hebrew University of Jerusalem, Israel
• Residency in General Oncology and Radiotherapy
• Training in the field of radiotherapy and brachytherapy at New York Hospital, USA
• Special refresher course for the treatment of tumors of the skeleton and soft tissues, Paris. France

Membership:

• President of the Society of oncologists and radiotherapists Israel
• The American Scientific Cancer Society
• European scientific medical organization
• European Society of Oncology of the musculoskeletal system
• International Society for the treatment of tumors of the connective tissue

Education & Expertise

• 1998 to 2004 – Istanbul University, Istanbul Faculty of Medicine
• 2005 to 2009 – Düzce University, Internal Medicine Specialization
• 2009 to 2010 – Beytüşşebap State Hospital, Compulsory Internal Medicine Service
• 2010 to 2013 – Bülent Ecevit University, Medical Oncology Specialization
• 2013 to 2015 – Recep Tayyip Erdoğan University, Medical Oncology Compulsory Service
• 2015 to Present – Associate Professor, Recep Tayyip Erdoğan University
• 2015 to 2021 – Lecturer, Medical Oncology, Sakarya University Faculty of Medicine
• 2020 to Present – Professor, Sakarya University Faculty of Medicine
• 2020 to Present – Ph.D. Student, Inorganic Chemistry, Sakarya University

Experience

• 2008 – Cleveland Clinic, Rheumatology & Gastroenterology Rotation
• 2016 to 2017 – Northeastern University, The Center for Pharmaceutical Biotechnology and Nanomedicine, Boston, U.S.

Professional Memberships

• TTOD (Turkish Society of Medical Oncology)
• ASCO (American Society of Clinical Oncology)
• ESMO (European Society for Medical Oncology)

Education and Career

2011 – 2015, (Internal Medicine Specialist) Istanbul University Istanbul School of Education and Career

Medicine Department of Internal Medicine

2015 – 2016, (Internal Medicine) Specialist Istanbul Haydarpasa Numune Training and Research Hospital

2016 – 2019, (Medical Oncology) Istanbul University Istanbul School of Medicine Department of Medical Oncology

2019 – 2021, (Medical Oncology Specialist) - Istanbul Haydarpasa Numune Training and Research Hospital

2021 – 2024, (Associate Professor) Marmara University School of Medicine Department of Medical Oncology

Memberships in Scientific Organizations

ASCO

ESMO

TTOD 

AVOD 

Publications

In the field of oncology, he has published over 30 peer-reviewed articles at both international and national levels.

Awards Received

EAACI The European Academy of Allergy and Clinical Immunology 2019 Best Poster Award

"The top 3rd verbal presentation, IGICC (11th International Gastrointestinal Cancers Conference – IGICC2021)"

Speeches Delivered at National Congresses, Conferences, and Symposia:

Courses, Meetings, and Certificates

ESMO certified Medical Oncologist since 2019

Dr. Verges graduated in Medicine and Surgery from the University of Barcelona in 1980 and moved to Boston (USA) to conduct basic research in ophthalmology, obtaining a PhD in Biology from Harvard University and defending his doctoral thesis on the mechanisms of tear secretion, which would become the basis for understanding the pathology of dry eye syndrome (thesis presented in Barcelona, ​​1983) and which earned him the National Research Prize (1983).

Currently, Dr. Carlos Verges carries out his professional activity as the Director of the Ophthalmology Service of the Dexéus University Hospital, together with his entire medical team from the advanced ophthalmology department, where he has a high-quality technological, medical and surgical team.

His area of ​​interest is focused on the field of cataract and neurophysiological mechanisms of vision, especially in relation to sports.

Professional experience

1983-1986 Associate Professor, Department of Ophthalmology, Faculty of Medicine, University of Barcelona, ​​Spain

1986-1989 Head of the Anterior Segment Unit, Department of Ophthalmology, Barcelona Hospital Clinic, Spain.

1986-1991 Professor of Ophthalmology, Faculty of Medicine, University of Barcelona, ​​Spain.

1990-1992 Head of Ophthalmology Service, Hospital del Mar, Barcelona.

1989-1999 Head of the Ophthalmology Department, Sagrada Familia Clinic, Barcelona, ​​Spain.

From 2000 to present, President and CEO of the Dr. Carlos Verges Private Foundation.

2000-2007 Head of the Ophthalmology Department, Institut Universitari Dexeus, Barcelona, ​​Spain.

2007 – present General Director of the “Advanced Ophthalmology Department Dr. Verges”, Barcelona, ​​Spain.

2018-present President and Head of the Department of Ophthalmology. University Hospital Dexeus Quironsalud. Polytechnic University of Catalonia.

Awards :

- National Research Prize 1984. Ministry of Education and Science: "The mechanism of tear secretion. The importance of beta-adrenergic receptors in the lacrimation of the lacrimal glands."

- National Prize for the best doctoral dissertation, Shibre Medal, 1984 "Personal contribution to the study of labial secretion. Determination of beta-adrenergic receptors in tear cells"

- National Pharmaceutical Industry Award 1987: "Treatment of immunological rejection in corneal transplantation using cyclosporine A."

- American Society of Implant Refractive Surgery (ASCRS) Award for the best scientific video presented at the annual conference: "Pseudo-Real Housing". First Prize. Seattle, USA, April 1999.

- Award for the most important technical innovation of 1999 from the Spanish Society.

Implantation-refractive surgery. Speaking at the National Congress held in Madrid 1999.

- 2000 Best Scientific Contribution Award "Laser Non-Penetrating Deep Sclerectomy" presented at the American Academy of Ophthalmology Meeting, AAO - Dallas, USA, October 2000.

- Best Paper Award for “GDx Analysis of Retinal Nerve Fiber Layer Thickness after LASIK” presented at the American Society of Cataract and Refractive Surgery, ASCRS, May 2004, San Diego, USA.

- Finalist for the King Jaume I Prize for Basic Research, 2005, sponsored by the Board of Trustees of the Generalitat of Valencia and the Valencian Foundation for Advanced Research.

- Surgical Technical Video Award: "MICS under Vision ICL, The Hook Technique"

Presented at the IX International Congress of Cataract and Refractive Surgery, May/June 2006, Belo Horizonte, Brazil.

Membership in scientific societies

Member of the Executive Board of the International Society of Refractive Surgery (ISRS) and the American Academy of Ophthalmology (AAO).

Member of the editorial board of Ophthalmology Times. Europe.

Member of the editorial board of Cataract and Refractive Surgery (USA).

Member of the Editorial Board of Cataract and Refractive Surgery Today Europe.

Member of the European Society of Cataract and Refractive Surgery (ESCRS).

Scientific reviewer of the journal: Cornea, Journal of Cataract and Refractive Surgery, American Academy of Ophthalmology, Cataract and Refractive Surgery and Archives of the Spanish Society of Ophthalmology.

Univ.-Prof. Dr. Wolfgang Johannes Köstler is a board-certified specialist for Internal Medicine, Hematology/Oncology, and Intensive Care Medicine who specializes in hematology & internal oncology, intensive care medicine. He is one of the top-rated breast cancer and sarcoma oncologist specialists and has extensive experience in the field and has received degrees from the Medical University of Vienna and the Weizmann Institute of Science. He has also had special training at Memorial Sloan-Kettering Cancer Center and Royal Prince Alfred Hospital.

Known Expertise 

Medical Oncologist 

Academic Position 

Senior Lecturer 

Education

Bar-Ilan University, Israel / Computational Biology 

Israeli Society for Health-Tech / Fellowship by IMA/ Innovation and Entrepreneurship in Medicine and Health-Tech 

Sheba Medical Center and Bar-Ilan University, Israel/ Genomics and Biomedical Informatics 

Semmelweis University/Doctor of Medicine 

Training and Specialization 

Clinical observership in acute oncology, early phase clinical trials and lung cancer/ Guy's and St. Thomas hospital, London, England 

Leader Shift, Executive Development Program, Tel-Aviv Sourasky Medical Center 

Fellowship Program in Innovation and Entrepreneurship in Medicine and Health-Tech 

Resident, Medical Oncology, TASMC, Israel 

6th year medical school rotations, Kaplan Medical Center, Israel 

Rotation, intensive care unit and pulmonology, Stony Brook hospital, NY, US 

Clinical Experience 

Leader of the TASMC oncology project of PSIFAS, the Israeli National Genomic Medicine Initiative 

PI for study initiator trial: T-Cell Repertoire sequencing as clinical efficacy tool for pembrolizumab (with platinum based chemotherapy) in advanced NSCLC. 

PI for study initiator trial: T-cell repertoire sequencing as a clinically efficacy tool for neoadjuvant immunotherapy plus platinum-doublet chemotherapy for resectable NSCLC. 

Representative of the National Medical Association for the National Council for the Prevention, Diagnosis and Treatment of Malignant Diseases, as well as head of the oncology field, Leumit HMO 

Consultant on drugs and operations in the field of oncology, Leumit HMO 

Member of the Helsinki Committee for Clinical Studies, TASMC 

Primary investigator (PI) in pharmaceutical phases I&III clinical trials Head of oncology day-care service, TASMC, Israel 

Molecular Tumor Board (MTB) moderator of the Israeli Lung Cancer Society 

NGS interpretation clinic alongside head of pathology, TASMC, Israel 

PI for study initiator trial: Genomic Variant of BCL-2 as a Novel Predictor of Response to Paclitaxel, TASMC, Israel 

Medical oncology clinic in the field of lung and breast cancer, TASMC, Israel

Leading sub-investigator (SI) in many phase I-III clinical trials in oncology, including intra-tumoral injections (mRNA, viruses and NO), TASMC, Israel 

Courses 

Good Clinical Practice ICH GCP R2 & Israeli MOH Guidelines Updated Course 

Point-of-Care Ultrasound course, Israeli Medical Association 

GCP training Bioforum 

GCP training Bioforum

Investigator Site Personnel ICH GCP Training Certificate - TransCelerate BioPharma 

Academic Experience 

Lecturer in the Department of Medical Education at the Faculty of Medical and Health Sciences at Tel Aviv University 

JIMS Journal Club - Instructor for students. 

Guidance of Dr. Aviv Berkovich M.D in basic science: cfDNA NGS for identification ofprimary and acquired resistance in patients with Lung Cancer and EGFR mutations. 

TASMC, Israel in collaboration with The Tisch Cancer Institute Icahn School of Medicine at Mount Sinai, NY USA 

Training team for oncology residents, TASMC, Israel 

Mentor for new intern, TASMC, Israel 

Tutor for medical students in oncology clerkships, Tel-Aviv University, Israel 

Honors 

Outstanding teacher in the faculty of medicine, Tel-Aviv University, Israel

 Outstanding teacher in the faculty of medicine, Tel-Aviv University, Israel 

Sign of honor for reserve medical personnel for the battle in Lebanon, IDF

Completion of residency final examination (shlav Beit) with honors 

Israeli society for clinical oncology and radiation therapy (ISCORT) 17 research grant competition winner 

Affiliations 

Israeli Medical Association (IMA) 

Israeli Society for Clinical Oncology and Radiation Therapy (ISCORT) 

The Israeli Lung Cancer Group (ILCG) 

European Society of Medical Oncology (ESMO) 

International Association for the Study of Lung Cancer (IASLC) 

The International Society of Liquid Biopsy (ISLB) 

The Israeli Society for Health-Tech 

Boards 

Co-founder, board member and treasurer of the Israeli Acute Oncology Society 

Clinical Research Association Board of Directors on behalf of the Israeli Lung Cancer Group 

Member of the Trustees of Oncology Innovation, TASMC, Israel 

Doctor of Medical Service IDF 

Areas of interest 

Thoracic malignancies, 

early to late phase clinical trials, 

intra-tumoral injections, 

comprehensive genomic profiling of tumors, 

liquid biopsies: cfDNA, TCR rep-seq and epi-Genetics; 

cell therapy

Dr. Viola Fox is the Chief Physician at the Clinic for Haematology, Oncology, and Palliative Medicine at BKZ Solingen. This clinic is a certified interdisciplinary cancer center. Dr. Fox is a leading expert in drug therapy for tumor diseases in Germany and Europe. She has more than 15 years of experience in this field.

She is a member of the German Society of Oncology and Haemato-oncology (GDHO), the German Association of Physicians, and the American Association for Cancer Research. Dr. Fox is also active in molecular biology research. Her work supports progress in cancer treatment and molecular diagnostics.

Her main areas of expertise are chemotherapy, immunotherapy, targeted therapy, and radiation therapy. Dr. Fox is known for her innovative methods and strong commitment to patient care. Her efforts have led to high recovery rates and recognition from her peers.

Dr. Ercan Ozden is a specialist in internal medicine and medical oncology. He earned his medical degree and completed his residency at Istanbul University, Cerrahpaşa Faculty of Medicine. He later received a subspecialty in medical oncology at Kocaeli University Faculty of Medicine from 2016 to 2020.

Dr. Ozden has worked in medical oncology at Şırnak State Hospital. He has also served as an internal medicine specialist at Bağcılar Private Safa Hospital and Küçükçekmece Batı Bahat Hospital. He has extensive clinical experience in both internal medicine and oncology.

PROFESSIONAL EXPERIENCE

2011-2012
Erzurum Koprukoyu State Hospital
Department: General Medicine

2012-2017
Istanbul University Cerrahpaşa Medical Faculty
Department: Internal Medicine

06/2017-10/2017
Istanbul Gaziosmanpasa Taksim Training and Research Hospital
Department: Internal Medicine

10/2017-11/2018
Istanbul University Istanbul Medical Faculty
Department: Allergy and Immunology Fellowship

2018/2022
Istanbul University Oncology Institute
Department: Medical Oncology Fellowship

2022-2023
Tekirdag City Hospital
Department: Medical Oncology Specialist

2023-present
Istanbul Medipol University Medipol Bahcelievler Private Hospital
Department: Medical Oncology Assoc. Prof.

EDUCATION

2005-2011
Medical Education
Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey

2012-2017
Internal Medicine
Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey

2017-2018
Allergy-Immunology Fellowship
Istanbul University Istanbul Medical Faculty
Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey

2018-2022
Medical Oncology Fellowship
Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey

2022
ESMO Board Certification in Medical Oncology
10th September 2022 in Paris, France.

2023
Medical Oncology Assoc. Prof.
Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey

INTERNATIONAL CLINICAL TRIALS:

1. Astefania - ROCHE

• Title: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
• Role: Subinvestigator

2. PFİZER

• Title: A Study Of Lorlatinib Versus Crizotinib In First-Line Treatment Of Patients With ALK-Positive NSCLC
• Role: Subinvestigator

3. RECITE - AMGEN

• Title: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
• Role: Subinvestigator

4. NAVIGATE - BAYER

• Title: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
• Role: Subinvestigator

5. RUBY - Tesaro (PRA)

• Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer
• Role: Subinvestigator

6. ENGOT-ov43/GOG-3036 - MSD

• Title: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK001/ENGOT-ov43/GOG-3036)
• Role: Subinvestigator

7. ASTRA ZENECA

• Title: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
• Role: Subinvestigator

8. ROSY-O - ASTRA ZENECA

• Title: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
• Role: Subinvestigator
•  

INTERNATIONAL PUBLICATIONS

I. Published journal articles indexed by SCI, SSCI, and AHCI

Weekly Paclitaxel in Classic Kaposi Sarcoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Ahmed, M. A., Karaman, S., & Aydiner, A.
• Journal: Medicine, 102(5)

Carboplatin Desensitization in Ovarian Carcinoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Yildiz, A., Ak, N., & Aydiner, A.
• Journal: Medicine, 101(45), e31726

High-Dose Chemotherapy for Ewing’s Sarcoma

• Authors: Paksoy, N., Ferhatoglu, F., Dogan, İ., Khanmammadov, N., Celik, A. I., Gulbas, Z., & Başaran, M.
• Journal: Medicine, 101(49), e32213

Multidrug Refractory TFE3(+) Renal Cell Carcinoma

• Authors: Paksoy, Nail, et al.
• Journal: Journal of Oncology Pharmacy Practice, 2022, 28.1: 215-221

Crizotinib Efficacy in NSCLC with MET Alterations

• Authors: Gürbüz, M., Kiliçkap, S., Bilici, A., Karadurmuş, N., Sezer, A., Şendur, M. A. N., ... & Demirkazik, A.
• Journal: Medicine, 101(50), e32368

Clinicopathological Features in ALK Mutant NSCLC

• Authors: Dogan, I., Gurbuz, M., Paksoy, N., Ferhatoglu, F., Vatansever, S., Saip, P., ... & Aydiner, A.
• Journal: Medicine, 101(34)

PSMA-Based Tumor Burden in Prostate Cancer

• Authors: HAS SIMSEK, Duygu, et al.
• Journal: Annals of Nuclear Medicine, 2021, 35.6: 680-690

Atezolizumab in Metastatic Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: European Urology Focus, 2021, 7.5: 1061-1066

Pulmonary Sarcomatoid Carcinoma

• Authors: FERHATOGLU, Ferhat, et al.
• Journal: Oncology Research and Treatment, 2021, 44.11: 590-601

Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: International Journal of Clinical Oncology, 2021, 26.8: 1506-1513

Atezolizumab with Chemotherapy in Small Cell Lung Cancer

• Authors: GÜRBÜZ, Mustafa, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 1-9

FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer

• Authors: AY, Seval, et al.
• Journal: Journal of Chemotherapy, 2022, 1-7

Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients

• Authors: CIL, Ibrahim, et al.
• Journal: Tumori Journal, 2022, 108.1: 19-25

Real-Life Efficacy of Osimertinib in Advanced NSCLC

• Authors: HIZAL, Mutlu, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 148.6: 1501-1508

ALK-Positive Cells Percentage and Alectinib Efficacy

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Atcı, M. M., Kahraman, S., Kılıçkap, S., ... & Şendur, M. A. N.
• Journal: Journal of Cancer Research and Clinical Oncology, 149(8), 4141-4148

Real-World Data on Alectinib in ALK-Positive NSCLC

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S., ... & Şendur, M. A. N.
• Journal: Future Oncology, 18(23), 2573-2582

Prognostic Factors in Metastatic RCC with T790M Mutation

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Desensitization Protocol in Lenalidomide Hypersensitivity Reactions

• Authors: DEMIR, Semra, et al.
• Journal: Annals of Allergy, Asthma & Immunology, 2019, 123.4: 394-397

Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity

• Authors: ÖZDEMIR, Seçil Kepil, et al.
• Journal: Allergy, 2019, 74.6: 1187-1190

Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors

• Authors: Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., ... & Sağlam, S.
• Journal: The Oncologist, oyad257

Subsequent Treatments in Hormone-Positive Breast Cancer Progression

• Authors: Karacin, C., Oksuzoglu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., ... & Hacıbekiroğlu, İ.
• Journal: BMC cancer, 23(1), 192

Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Saip, P., & Aydiner, A.
• Journal: Scientific Reports, 13(1), 8779

Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Ferhatoğlu, F., Ak, N., ... & Aydiner, A.
• Journal: Journal of Cancer Research and Clinical Oncology, 1-9

Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer

• Authors: Doğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydıner, A.
• Journal: European Journal of Breast Health, 19(2), 128

Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer

• Authors: Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... & Nahit Sendur, M. A.
• Journal: Future Oncology, 19(10), 727-736

Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer

• Authors: Erol, C., Sakin, A., Basoglu, T., Ozden, E., Cabuk, D., Dogan, M., ... & Sendur, M. A. N.
• Journal: [Not specified]

Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma

• Authors: Khanmammadov, N., Paksoy, N., Doğan, I., Ferhatoğlu, F., Saip, P., & Aydiner, A.
• Journal: Medicine, 102(39), e35383

Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma

• Authors: Pehlivan, M., Paksoy, N., Aydin, E., Basaran, M., & Ekenel, M.
• Journal: Medicine, 102(41), e35245

Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)

Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)

Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.

Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49

Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4

Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.

Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY

Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology

Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)

Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)

Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)

Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)

Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye

Thesis:

Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)

International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)

Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination

• Authors: Dogan, I., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydiner, A. (2022)

Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study

• Authors: Şenocak Taşçi, E., Oyan, B., Sonmez, O., Mutlu, A. U., Atcı, M. M., Oner, I., ... & Gulmez, A. (2022)

Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer

• Authors: Dogan, I., Aydin, E., Paksoy, N., Ferhatoglu, F., Ak, N., Ibis, K., ... & Aydiner, A. (2021)

Efficacy of temozolomide in pretreated patients with metastatic sarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors

• Authors: Ferhatoglu, F., Paksoy, N., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases

• Authors: Dogan, İ., Iribas, A., Paksoy, N., Ekenel, M., Vatansever, S., & Basaran, M. (2021)

Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma

• Authors: Tural, D., Olmez, O. F., Sümbül, A. T., Artac, M., Ozhan, N., Akar, E., ... & Erman, M. (2021)

Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study

• Authors: Esin, E., Ahmed, M. A., Yıldırım, H. Ç., Mandel, N. M., Erdemoglu, E., Sari, M., ... & Paydas, S. (2023)

Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences

• Authors: Tural, D., Ölmez, Ö. F., Sümbül, A. T., Artaç, M., Özhan, N., Akar, E., ... & Kılıçkap, S. (2021)

Education and Specialization

• 2006: Kocaeli University Faculty of Medicine
• 2014: Akdeniz University Faculty of Medicine, Internal Medicine
• 2018: Akdeniz University Faculty of Medicine, Medical Oncology

Experience

• 2006 - 2008: Konya Derebucak District Hospital
• 2009 - 2015: Akdeniz University Hospital
• 2015: Antalya Kaş State Hospital
• 2015 - 2016: İnönü University Faculty of Medicine
• 2016 - 2021: Akdeniz University Hospital
• 2021 - 2023: Antalya Training and Research Hospital

Dr. Raj Nagarkar is a leading Surgical Oncologist with 19 years of experience. He has performed over 50,000 cancer surgeries. His main focus areas are Breast and Thoracic Surgical Oncology. He is involved in more than 200 clinical trials and has contributed to many national and international publications.

Dr. Nagarkar trained in Surgical Oncology at Tata Memorial Hospital, Mumbai. He also holds an MRCS from the Royal College of Surgeons, Edinburgh. He teaches DNB Superspecialty Surgical Oncology and Breast Surgery at Maharashtra University of Health Sciences. Dr. Nagarkar is dedicated to improving the quality of life for his patients.

Dr. Sridhar P.S. is a skilled radiation oncologist. He earned his Bachelor of Medicine from Mysore University. He completed his MD in Radiotherapy at Banaras Hindu University. He also holds a Diplomate of the National Board in Radiotherapy. This shows his advanced training and dedication to quality care.

Dr. Sridhar is a member of several professional groups. These include the Association of Radiation Oncology of India, Society for Neuro-Oncology, Bangalore Oncology Group, and the Indian Association of Hyperthermia Oncology. He is known for his effective cancer treatments and focus on new therapies. His work has made a positive impact in the field of oncology.

Dr. Chaitainya Borde is a nuclear medicine specialist with 12 years of clinical experience. He is skilled in advanced nuclear scans, PET-CT imaging, and nuclear cardiology. He works in both diagnostic and therapeutic nuclear medicine.

Dr. Borde has performed over 30,000 PET scans. He has managed more than 1,000 thyroid cancer patients. He is experienced in radioiodine and Lu-177 RN therapies. He has also published research papers in respected medical journals, showing his dedication to academic work.

Dr. Shruti Kate is an experienced oncologist. She specializes in treating lung, breast, gynecological, and genitourinary cancers. She earned her MBBS from Lady Hardinge Medical College. She completed her MD in Internal Medicine at Maulana Azad Medical College. She also holds a DM in Medical Oncology from Tata Memorial Hospital, Mumbai.

Dr. Kate has managed both conservative and surgical cancer treatments. She is skilled in complex procedures such as the Whipple surgery. She is a member of several leading oncology societies, including ASCO, ESMO, IASCLC, ISMPO, and IOS. Her research on lung cancer received the only travel award from India at the 2018 World Conference on Lung Cancer.

Dr. Ahmer Arif Shaikh, MDS (Oral & Maxillofacial Surgery), is a specialist in Surgical Oncology. He has 3 years of experience at HCG Manavata Cancer Centre, Nashik. He focuses on oral cancer treatment, organ preservation, and functional rehabilitation for oral cancer patients.

Dr. Shaikh has completed a Fellowship in Head & Neck Surgical Oncology. He is skilled in complex maxillofacial and head & neck surgeries. He is also an active researcher with several publications in reputed journals. His work shows a strong commitment to improving cancer care.

Dr. Lalit Banswal is an experienced oncological surgeon with 10 years in the field. He has performed more than 10,000 major surgeries. He earned his MBBS from MIMER, Pune, and completed his MS at GMC Panaji. He also completed a fellowship in Surgical Oncology at Tata Medical Centre, Kolkata, with a focus on gastrointestinal cancers.

Dr. Banswal has worked as a Co-principal Investigator in several research projects. He has published his work in both national and international journals. He is known for his patient-friendly and ethical approach. His main expertise is in Minimal Invasive Cancer Surgeries, where he consistently delivers excellent results.

Dr. Shaunak Valame is an MD in Internal Medicine and holds a DNB in Medical Oncology. He received advanced training at Indraprastha Apollo Hospital in New Delhi. He also worked as a Registrar at Jawaharlal Nehru Cancer Hospital in Bhopal. Dr. Valame has presented his research at international forums, including the Gastrointestinal Cancer Symposium in San Francisco.

He is known for his work in targeted cancer therapies. He has given lectures at the International Winter School of Oncology at AIIMS Bhopal. Dr. Valame is accredited by the American Society of Clinical Oncology. He is committed to advancing cancer research and clinical care.